BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ajinomoto Aminoscience LLC Showcases New Commercial Opportunities of Recombinant Protein Technology


9/8/2010 10:59:11 AM

RALEIGH, NC – SEPTEMBER 8, 2010 – Ajinomoto Aminoscience LLC (AAS) today announced availability of a new whitepaper that outlines the common challenges associated with recombinant protein production and discusses how novel expression systems, such as the CorynexTM Recombinant Protein Expression System, are helping simplify the production process, reduce costs, and speed time to market.

Along with highlighting CorynexTM, the new whitepaper, entitled “Speeding and Simplifying Recombinant Protein Production,” also examines market drivers of recombinant protein production, challenges unique to each protein, benefits and drawbacks of expression systems (bacteria, yeast, and mammalian host cells), as well as key considerations and questions to ask when selecting a production process.

Recombinant protein technology provides a wealth of commercial opportunities. However, production is time-consuming, costly and subject to technical pitfalls. In addition, conventional microbe-based expression systems often use micro-organisms such as E. coli, pseudomonas and yeast, which require multiple purification steps, additional subsequent refolding and may contribute impurities. Traditionally, overcoming these challenges has meant refining or optimizing individual steps within the production process.

Ajinomoto’s CorynexTM Recombinant Protein Expression System uses a specially-developed gram-positive bacterium, Corynebacterium glutamicum. The expression system secretes correctly-folded, active proteins directly into the growth media with minimal host cell protein secretion and no endotoxins. By secreting active proteins directly into the growth media, Corynex eliminates the need for extensive downstream processing and additional refolding steps, which often result in 50% to 80% losses in target proteins.

In addition to developing the whitepaper, Ajinomoto has also created an educational video that uses computer-generated animation to illustrate protein expression in a way that’s never before been seen. The video provides an in-depth look at the expression and export of recombinant proteins from Corynebacterium glutamicum compared to E. coli and demonstrates how CorynexTM allows the recombinant protein to be readily purified directly from the fermentation broth.

To download a free copy of the whitepaper, “Speeding and Simplifying Recombinant Protein Production” and view the revolutionary new 3D animation of Ajinomoto’s CorynexTM Recombinant Protein Expression System, please visit www.corynex.com.

About Ajinomoto AminoScience, LLC

Ajinomoto is the leading supplier of pharmaceutical and research-grade amino acids in the US and throughout the world. Leveraging its unrivaled foundation of more than 50 years of experience identifying, refining, and marketing amino acids, Ajinomoto AminoScience, LLC (AAS) continues to innovate and set new industry standards for manufacturing and related services within the fermentation and expression fields. Building on its legacy, AAS has transitioned the same level of quality and performance into new core competencies in the areas of recombinant protein expression and peptide synthesis. These new processes enable pharmaceutical and bio-tech companies to develop high-quality products that were previously thought to be too complicated or expensive to produce. The CorynexTM Recombinant Protein Expression System is a streamlined, more efficient process to produce complex human proteins for pharmaceutical use using a specially-developed gram-positive bacterium, Corynebacterium glutamicum. The AjiPhase™ service enables the use of a single peptide synthesis methodology throughout therapeutic peptide development as peptide requirements increase. Ajinomoto AminoScience, LLC is a part of Ajinomoto USA Inc., a wholly-owned subsidiary of Ajinomoto Co., Inc. For more information on AAS and its products and services, please refer to http://www.ajiaminoscience.com/Default.aspx



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES